Daftar Pustaka

Alnagdy A, Eissa AM, El-Kannishy A. Topical NSAIDs in Prevention of Postcataract Macular Edema. InFrontiers in Ophthalmology and Ocular Imaging 2019 Apr 30. IntechOpen.

Arcieri ES, Santana A, Rocha FN, Guapo GL, Costa VP. Bloodaqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol. 2005;123(2):186-192.

Agarwal R, Srivastava S. Textbook on clinical ocular pharmacology & therapeutics. JP Medical Ltd; 2014 Sep 30.

Akcay BI, Bozkurt TK, Guney E, et al. Quantitative analysis of macular thickness following uneventful and complicated cataract surgery. Clin Ophthalmol. 2012;6:1507–1511.

Alm A, Grunden JW, Kwok KK. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. J Glaucoma. 2011;20(4):215e22

Appukuttan, B., Giridhar, A., Gopalakrishnan, M. and Sivaprasad, S., 2014. Normative spectral domain optical coherence tomography data on macular and retinal nerve fiber layer thickness in Indians. *Indian journal of ophthalmology*, *62*(3), p.316.

American Academy of ophthalmology. Retina and vitreus. Chapter 2; Diagnostic Approach to retinal Disesase. 2019-2020.

Bartlett JD, Jaanus SD. Clinical ocular pharmacology. Elsevier Health Sciences; 2007 Nov 12.

Bélair M, Kim SJ, Thorne JE, et al. Incidence of cystoid macular edema after cataract surgery in patients with and without uveitis using optical coherence tomography. Am J Ophthalmol. 2009;148:135.e2.

Bille, J.F. ed., 2019. High Resolution Imaging in Microscopy and Ophthalmology: New Frontiers in Biomedical Optics. Springer.

Bhende, M., Shetty, S., Parthasarathy, M.K. and Ramya, S., 2018. Optical coherence tomography: A guide to interpretation of common macular diseases. Indian journal of ophthalmology, 66(1), p.20.m

B. Von Jagow, C. Ohrloff, and T. Kohnen, “Macular thickness after uneventful cataract surgery determined by optical coherence tomography,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 245, no. 12, pp. 1765–1771, 2007.

Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q, Yang YC. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes. Ophthalmology. 2016;123(2):316-323.

Conway MD, Canakis C, Livir-Rallatos C, Peyman GA. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg. 2003;29(1):27–33.

Diabetic Retinopathy Clinical Research Network Writing Committee, Bressler SB, Edwards AR, Chalam KV, Bressler NM, Glassman AR, et al. Reproducibility of spectral-domain optical coherence tomography retinal thickness measurements and conversion to equivalent time-domain metrics in diabetic macular edema. JAMA Ophthalmol 2014;132:1113-22.

Doughty MJ. Ocular Pharmacology & Therapeutics. Butterworth-Heinemann; 2001.

Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998;96:557e634

Girkin CA, McGwin G Jr. Sinai MJ, Sekhar GC, Fingeret M, Wollstein G, et al. Variation in optic nerve and macular structure with age and race with spectral-domain optical coherence tomography. Ophthalmology 2011;118:2403-8.

Grzybowski, A., Sikorski, B.L., Ascaso, F.J. and Huerva, V., 2016. Pseudophakic cystoid macular edema: update 2016. *Clinical interventions in aging*, *11*, p.1221.

Grzybowski A, Zemaitiene R, Mikalauskiene L. Post-cataract cystoid macular oedema prevention–update 2019.

Guo S, Patel S, Baumrind B, et al. Management of pseudophakic cystoid macular edema. Surv Ophthalmol. 2015;60(2):123e37

Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg. 2007;33(9):1550-1558.

Ilic J, Grigon S, Leuenberger PM. Comparison de *I'eftet* anti-inflammatoire des collyres de Dexamethasone et de Diclofenac. Klin Monatsbl Augenheilk 1984; 184: 494-8.

J. C. Brown, S. D. Solomon, S. B. Bressler, A. P. Schachat,C. DiBernardo, and N. M. Bressler, “Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography,” Archives of Ophthalmology, vol. 122, no. 3, pp. 330–335, 2004.

J. S. Heier, T. M. Topping, W. Baumann, M. S. Dirks, and S. Chern, “Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema,” Ophthalmology, vol. 107, no. 11, pp. 2034–2038, 2000.

J. R. Wolter, “The histopathology of cystoid macular edema,” Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie, vol. 216, no. 2, pp. 85–101, 1981.

Law SK, Kim E, Yu F, Caprioli J. Clinical cystoid macular edema after cataract surgery in glaucoma patients. J Glaucoma. 2010;19 (2):100-104.

Nguyen, P. and Chopra, V., 2013. Applications of optical coherence tomography in cataract surgery. Current opinion in ophthalmology, 24(1), pp.47-52.

Guo S, Patel S, Baumrind B, et al. Management of pseudophakic cystoid macular edema. Surv Ophthalmol. 2015;60:123–137.

Han JV, Patel DV, Squirrell D, McGhee CN. Cystoid macular oedema following cataract surgery: a review. Clinical & experimental ophthalmology. 2019 Apr;47(3):346-56.

Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macu- lar edema. Risk factors for development and duration after treatment. J Cataract Refract Surg. 2007;33(9):1550-8.

Hernstadt DJ, Husain R. Effect of prostaglandin analogue use on the development of cystoid macular edema after phacoemulsification using STROBE statement methodology. J Cataract Refract Surg. 2017;43(4):564e9

Hirnschall, N., Leisser, C., Radda, S., Maedel, S. and Findl, O., 2016. Macular disease detection with a swept-source optical coherence tomography-based biometry device in patients scheduled for cataract surgery. Journal of Cataract & Refractive Surgery, 42(4), pp.530-536.

Hudes GR, Li WY, Rockey JH, White P. Prostacyclin is the major p taglandin synthesized by bovine retinal capillary pericytes in culture. Invest Ophthalmol Vis Sci. 1988;29:1511–1516.

Hoffman RS, Braga-Mele R, Donaldson K, Emerick G, Henderson B, Kahook M, Mamalis N, Miller KM, Realini T, Shorstein NH, Stiverson RK, Wirostko B, for the ASCRS Cataract Clinical Committee and the American Glaucoma Society. Cataract surgery and nonsteroidal antiinflammatory drugs. J Cataract Refract Surg 2016; 42:1368–1379.

Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55(2):108–133.

McColgin AZ, Raizman MB. Efficacy of topical Voltaren in reducing the incidence of postoperative cystoid macular edema. Invest Ophthalmol Vis Sci 1999;40(Suppl):289

McGhee C, et al. Penetration of synthetic corticosteroids into hu- man aqueous humour. Eye. 1990;4(3):526–30.

McGhee CN. Pharmacokinetics of ophthalmic corticosteroids. The British journal of ophthalmology. 1992 Nov;76(11):681.

McGhee CNJ, Noble MJ, Watson DG, Dutton GN, Fern Al, Healey TM, et al. Penetration of topically applied prednisolone sodium phosphate into human aqueous humour. Eye 1989; 3: 463-7.

Melancia D, Pinto A, Marques-Neves C. Cataract surgery and intraocular pressure. *Ophthalmic Res.* 2015;53:141–8.

Ouyang Y, Keane PA, Sadda SR, Walsh AC. Detection of cystoid macular edema with three- dimensional optical coherence tomogra- phy versus fluorescein angiography. Invest Ophthalmol Vis Sci. 2010;51(10):5213-5218.

O'Brien TP. Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Med Res Opin. 2005;21(7):1131-7.

Perente I, Utine CA, Ozturker C, et al. Evaluation of macular changes after uncomplicated phacoemulsification surgery by optical coherence tomography. Curr Eye Res. 2007;32(3):241–247.

Rho DS. Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J Cataract Refract Surg 2003;29:2378-84

Scholer DW, Ku EC, Boettcher I, Schweizer A. Phar- macology of diclofenac sodium. Am J Med 1986; 80 (sup- pi 4B): S34-8.

Song P, Wang H, Theodoratou E, et al. The national and subnational prevalence of cataract and cataract blindness in China: a systematic review and meta-analysis. *J Glob Health*. 2018;8:010804.

Soliman W, Sander B, Jørgensen T. Enhanced optical coherence patterns of diabetic macular oedema and their correlation with the pathophysiology. Acta Ophthalmologica. 2007;85:613-617. DOI: 10.1111/j.1600-0420.2007.00917.x

Sahin M, Cingu AK, Gozum N. Evaluation of cystoid macular edema using optical coherence tomography and fundus autofluorescence after uncomplicated phacoemulsification surgery. J Ophthalmol. 2013;2013: 376013.

Schmier JK, Halpern MT, Covert DW, Matthews GP. Evaluation of costs for cystoid macular edema among patients after cataract surgery. Retina. 2007;27(5):621-628.

Sigler EJ, Randolph JC, Kiernan DF. Longitudinal analysis of the structural pattern of pseudophakic cystoid macular edema using multimodal imaging. Graefes Arch Clin Exp Ophthalmol. 2016;254(1):43e51

Simone JN, Whitacre MM. Effects of anti-inflammatory drugs following cataract extraction. Curr Opin Ophthalmol. 2001;12(1):63–67.

S. Sivaprasad, C. Bunce, and R. Wormald, “Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review,” British Journal of Ophthalmology, vol. 89, no. 11, pp. 1420–1422, 2005.

Staurenghi G, Invernizzi A, de Polo L, Pellegrini M. Diagnosis and detection. Eur J Ophthalmol. 2011;21(Suppl. 6):S27e36

Tsilimbaris MK, Tsika C, Diakonis V, Karavitaki A, Pallikaris I.Macular edema and cataract surgery, in cataract surgery. In: Zaid F, editor. Cataract Surgery. InTech. 2013: ISBN 978-953-51-0975-4.

Tatrai E, Ranganathan S, Ferencz M, Cabrera DeBuc D, Somfai GM. Comparison of retinal thickness by Fourier-domain optical coherence tomography and OCT retinal image analysis software segmentation analysis derived from Stratus optical coherence tomography images. J Biomed Opt. 2011;16(5):056004.

Ursell PG, Spalton DJ, Whitcup SM, Nussenblatt RB. Cystoid m lar edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity. J Cataract Refract Surg. 1999;25: 1492–1497.

Wilkinson CP, Hinton DR, Sadda ST, et al. Ryan's Retina, sixth edition

Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK, Iliev ME, Frey M, Rothenbuehler SP, et al. Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci 2009;50:3432-7.

Wolf EJ, Braunstein A, Shih C, Braunstein RE. Incidence of visu- ally significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac. J Cataract Refract Surg. 2007;33(9):1546-9.

Wright PL, Wilkinson CP, Balyeat HD, Popham J, Reinke M. A graphic cystoid macular edema after posterior chamber lens implantation. Arch Ophthalmol. 1988;106(6):740–744.

DAFTAR LAMPIRAN

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed.PhD. SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 577/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 8 September 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21070467	No Sponsor Protokol	
Peneliti Utama	**dr. M. Anugrah Fadhil**	Sponsor	
Judul Peneliti	Efektifitas Topikal NSAID dan Kortikosteroid Terhadap Ketebalan Makula Pasca Operasi Fekoemulsifikasi		
No Versi Protokol	**2**	Tanggal Versi	**26 Agustus 2021**
No Versi PSP	**2**	Tanggal Versi	**26 Agustus 2021**
Tempat Penelitian	RS Universitas Hasanuddin dan Klinik Mata JEC-Orbita Makassar		
Jenis Review	☐ Exempted ☐ Expedited ☒ Fullboard Tanggal **25 Agustus 2021**	Masa Berlaku **8 September 2021** sampai **8 September 2022**	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

KEMENTRIAN RISET, TEKNOLOGI DAN PENDIDIKAN TINGGI
KOMITE ETIK PENELITIAN KESEHATAN
Fakultas Kedokteran Universitas Hasanuddin
RSPTN Universitas Hasanuddin
RSUP dr. Wahidin Sudirohusodo Makassar
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu FKUH
JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10, MAKASSAR 90245
Contact Person: dr. Agussalim Bukhari, M.Med, Ph.D, Sp.GK 081241850858.
e-mail:agussalimbukhari@yahoo.com

Lampiran 1.

NASKAH PENJELASAN PADA SUBYEK

Selamat pagi/siang, Assalamu'alaykum Bapak/Ibu/Saudara(i), saya dr. M. Anugrah Fadhil, dokter peserta program pendidikan dokter spesialis pada bagian Ilmu Kesehatan Mata, Fakultas Kedokteran Universitas Hasanuddin. Kami bermaksud akan melakukan penelitian mengenai Efektifitas tetes mata anti radang *Non steroid anti inflamatory drug* (NSAID) dengan nama obat NONCORT dan obat tetes kortikosteroid dengan nama obat P.PRED setelah operasi katarak fekoemulsifikasi (laser)

Kami bermaksud melakukan penelitian ini untuk menilai ketebalan makula (bagian tengah retina atau saraf mata) dan inflamasi (radang) pada segmen anterior (bagian depan) bola mata setelah operasi fekoemulsifikasi. Pemeriksaan bagian depan bola mata merupakan pemeriksaan rutin yang dilakukan dengan menggunakan alat slit lamp (lampu celah) setelah operasi katarak, sedangkan pemeriksaan ketebalan makula menggunakan alat *non contact* (tidak kontak) dengan bola mata bagian depan dan tidak invasi yaitu *Optical Coherance Tomography* (OCT) untuk mengevaluasi ketebalan makula yang dilakukan 1 kali sebelum operasi kemudian pada hari ke-7 dan ke-30 setelah operasi. Pemberian obat tetes topikal Noncort 1 tetes diberikan pada 1 jam kemudian 1/2 jam sebelum operasi lalu dilanjutkan 1 tetes tiap 8 jam selama 4 minggu setelah operasi fekoemulsifikasi. Pemberian obat tetes topikal P-Pred diberikan 1 jam kemudian 1/2 jam sebelum operasi lalu dilanjutkan 1 tetes tiap 6 jam selama 4 minggu.

Informasi ilmiah yang dapat diperoleh pada penelitian ini adalah untuk mengetahui efektivitas obat anti radang dalam mempengaruhi ketebalan makula yang dapat berdampak pada pengelihatan Bapak/Ibu, selain itu informasi lain yang diperolah adalah tingkat peradangan yang terjadi setelah dilakukan penetesan obat anti radang

mulai sebelum hingga setelah operasi. Penggunaan kacamata tidak berhubungan dengan pemberian tetes mata yang diberikan setelah operasi. Kacamata diberikan bila 1 bulan setelah operasi katarak perlu dilakukan koreksi refraksi.

Kami sangat mengharapkan kesediaan Bapak/Ibu untuk mengikuti penelitian ini. Penelitian ini bersifat sukarela tanpa ada paksaan, sehingga Bapak/Ibu dapat menolak atau mengundurkan diri dari penelitian ini kapan saja jika terdapat hal-hal yang tidak berkenan terhadap Bapak/Ibu dan tidak akan mengurangi kualitas pelayanan terhadap Anda. Pengunduran diri tersebut tidak akan mengurangi atau mengubah mutu pelayanan dari dokter. Bila masih ada hal-hal yang Bapak/Ibu ingin ketahui, maka Bapak/Ibu dapat bertanya atau meminta penjelasan pada kami di Departemen Ilmu Kesehatan Mata RS Unhas, atau secara langsung melalui nomor telepon saya : dr. M. Anugrah Fadhil (082393277760). Pada penelitian ini identitas Bapak/Ibu disamarkan. Hanya dokter peneliti dan anggota komisi etik yang bisa melihat data anak Bapak/Ibu. Kerahasiaan data Bapak/Ibu sepenuhnya akan dijamin. Bila data akan dipublikasikan kerahasiaan akan tetap dijaga. Data pada penelitian ini akan dikumpulkan dan disimpan dalam *file* manual dan elektronik, diaudit, diproses dan dipresentasikan pada:

- Forum ilmiah Deaprtemen Ilmu Kesehatan Mata, Fakultas Kedokteran Unhas
- Forum ilmiah kegiatan PERDAMI
- Publikasi pada jurnal ilmiah dalam maupun luar negeri

Jika Bapak/Ibu setuju untuk berpartisipasi, diharapkan menandatangani surat persetujuan mengikuti penelitian. Atas kesediaan dan kerjasamanya kami ucapkan terima kasih.

Identitas peneliti

Nama : dr. M. Anugrah Fadhil
Alamat : Jl. Tala Salapang II komp P&K Blok J.No.2.
Telepon : 082393277760

DISETUJUI OLEH KOMISI
PENELITIAN KESEHATAN
FAKULTAS KEDOKTERAN
UNHAS TGL 8 SEPTEMBER 2021

KEMENTRIAN RISET, TEKNOLOGI DAN PENDIDIKAN TINGGI
KOMITE ETIK PENELITIAN KESEHATAN
Fakultas Kedokteran Universitas Hasanuddin
RSPTN Universitas Hasanuddin
RSUP dr. Wahidin Sudirohusodo Makassar
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu FKUH
jl. Perintis kemerdekaan kampus tamalanrea km.10, makassar 90245. Contact Person: dr. Agussalim Bukhari, M.Med, Ph.D, Sp.GK 081241850858. e-mail:agussalimbukhari@yahoo.com

Lampiran 2.

FORMULIR PERSETUJUAN

Saya yang bertanda tangan di bawah ini :
Nama : …… Umur: ..... tahun
Alamat : ……
Telepon/HP : .....

Menyatakan bersedia untuk berpartisipasi pada penelitian ini yang berjudul :

EFEKTIVITAS TOPIKAL NSAID DAN KORTIKOSTEROID TERHADAP KETEBALAN MAKULA PASCA OPERASI FEKOEMULSIFIKASI

setelah mendengar/membaca dan mengerti penjelasan yang diberikan mengenai tujuan dan manfaat yang akan didapatkan pada penelitian ini, khususnya bagi kemajuan ilmu kedokteran.

Makassar,
.....

Saksi I Saksi II

(.....) (.....)

Penanggung jawab penelitian :
dr. M. Anugrah Fadhil
Jl. Tala Salapang II. Komp P&K Blok J. No. 2
Telp. 082393277720

Penanggung jawab medik :
dr. Hamzah, Sp.M(K)
Jl. Pendidikan D4/15 Komp. IKIP
Telp. 08164384460

DISETUJUI OLEH KOMISI
PENELITIAN KESEHATAN
FAKULTAS KEDOKTERAN UNHAS
TGL 8 SEPTEMBER 2021

DATA PASIEN

Kelompok P-Pred post

No	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
NAMA	**YOHANES**	**YEONGJI**	**LABABA**	**ANSHAR**	**MUSTAMIN**	**FATMAWATI**	**USMAN**	**MARTINUS**	**RAHMI YAHYA**	**HASLI SABANG**	**DUMA ISHAK**	**ABDULLAH SYAKUR**	**ABU THALIB**	**DAHRIAH**	**ANNA MARIA**	**RONNY**
RM	147225	108109	146856	144472	148267	148299	148294	148295	148204	113394	148628	145401	130607	147604	151641	261289
MATA	**KANAN**	**KIRI**	**KIRI**	**KIRI**	**KANAN**	**KANAN**	**KIRI**	**KIRI**	**KIRI**	**KIRI**	**KANAN**	**KIRI**	**KIRI**	**KANAN**	**KIRI**	**KIRI**
OP	**10-12-2021**	**17/12/2021**	**18/12/2021**	**24/12/2021**	**24/12/2021**	**27/12**	**27/12/2021**	**27/12/2021**	**03/01/2022**	**03/01/22**	**14/2/2022**	**14/2/2022**	**18/02/2022**	**4/3/2022**	**21/3/2022**	**21/3/2022**
UMUR	64	73	61	64	67	68	62	59	67	62	66	75	61	67	65	66
JK	LAKI-LAKI	PEREMPUAN	LAKI-LAKI	LAKI-LAKI	LAKI-LAKI	PEREMPUAN	LAKI-LAKI	LAKI-LAKI	PEREMPUAN	LAKI-LAKI	LAKI-LAKI	LAKI-LAKI	LAKI-LAKI	PEREMPUAN	PEREMPUAN	LAKI-LAKI
PRE OP																
Visual Acuity (Decimal)	0,03	0,3	0,1	0,28	0,1	0,32	0,32	0,32	0,28	0,2	0,30	0,1	0,03	0,03	0,25	0,1
Visual Acuity (LogMar)	1,52	0,52	1,00	0,55	1,00	0,49	0,49	0,49	0,55	0,70	0,52	1,00	1,52	1,52	0,60	1,00
IOP (mmHg)	17	16	17	14	14	12	23	13	14	23	14	16	20	13	17	15
CENTRAL MACULAR THICKNESS(µm)	256	238	284	210	254	233	240	235	231	247	285	239	261	235	228	218
VOL (mm2)	9,5	9,7	10,2	7,2	9,6	9,5	11	9,2	10,2	9,5	10,5	9,4	9,8	8,2	9	9,4
THICK. AVG µm)	264	269	282	200	267	263	305	258	282	265	291	262	271	229	249	262
OP																
Phacoemusification time (sec)	37,4	0,8	40,8	37,4	78,1	54,6	43,4	15,0	28,2	19,7	69,4	46,9	54,3	53,8	37,4	0,8
Effective phaco time (sec)	6,4	2,0	3,7	6,4	14,4	3,9	4,8	1,3	2,0	1,5	10,7	5,9	9,1	10,6	6,4	2,0
Operation time (minute)	10,0	14,0	7,0	15,0	12,0	10,0	10,0	10,0	10,0	10,0	10,0	10,0	10,0	14,0	10,0	14,0
POST OP H+1																
Visual Acuity (Decimal)	0,01	0,1	0,1	0,01	0,01	0,6	0,25	0,1	0,2	0,25	0,5	0,3	0,05	0,3	0,2	0,8
Visual Acuity (LogMar)	2,00	1,00	1,00	2,00	2,00	0,22	0,60	1,00	0,70	0,60	0,30	0,52	1,30	0,52	0,70	0,10
IOP (mmHg)	27	25	20	26	28	19	27	20	19	23	16	20	29	15	23	14
CELL	1	1	1	1	0,5	0,5	0,5	1	1	0,5	0,5	0,5	1	0,5	1	0
FLARE	1	1	1	1	1	1	0	1	1	0	0	0	1	0	2	0
CONJ.HIPEREMIS	2	1	2	1	1	1	1	1	1	1	0	0	1	1	1	0

PAIN (VAS)	1	0	1	1	0	1	0	1	1	1	0	1	0	1	1	0
POST OP H+7																
Visual Acuity (Decimal)	0,28	0,5	0,5	0,01	0,6	0,6	0,5	0,6	0,4	0,28	0,5	0,5	0,5	0,8	0,6	1
Visual Acuity (LogMar)	0,55	0,30	0,30	2,00	0,22	0,22	0,30	0,22	0,40	0,55	0,30	0,30	0,30	0,10	0,22	0,00
IOP (mmHg)	17	16	20	18	13	19	13	12	15	18	15	15	16	12	14	12
CENTRAL MACULAR THICKNESS(µm)	266	251	290	217	265	210	241	232	230	259	283	241	258	220	230	209
VOL (mm2)	10,1	9,7	10,4	6,8	9,8	9,3	11	9,4	9,8	9,9	10,6	10,3	10	9,5	9,3	9,2
THICK. AVG µm)	281	270	289	190	271	257	302	262	272	274	294	285	277	263	259	255
CELL	0,5	0	0	0,5	0	0	0	0,5	0,5	0	0	0	0,5	0	0,5	0
FLARE	0	0	0	1	0	0	0	1	1	0	0	0	1	0	1	0
CONJ.HIPEREMIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
PAIN	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
POST OP 30																
Visual Acuity (Decimal)	1	1	0,8	0,2	1	0,8	1	0,6	1	0,8	1	0,6	1	1	1	1
Visual Acuity (LogMar)	0,00	0,00	0,10	0,70	0,00	0,10	0,00	0,22	0,00	0,10	0,00	0,22	0,00	0,00	0,22	0,00
IOP (mmHg)	19	12	17	11	12	17	16	13	11	17	14	16	16	11	15	13
CENTRAL MACULAR THICKNESS(µm)	284	247	301	222	264	214	229	250	226	270	306	257	260	228	238	234
VOL (mm2)	10,6	10,1	10,6	8,5	9,8	9,3	11	9,6	9,6	10	10,3	10,8	10,2	9,6	9,6	9,5
THICK. AVG µm)	294	280	294	237	273	259	306	268	267	279	287	299	282	266	267	264
CELL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FLARE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONJ.HIPEREMIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
PAIN	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Kelompok P-Pred pre-post

No	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
NAMA	**MANTANG**	**ZAENUDDIN**	**MUHSIN**	**DIAH**	**MUSTAMIN**	**SITTI KATRIAH**	**HAJERAH**	**DEBORAH**	**YOHANES**	**FATMAWATI**	**LADANDANG**	**SUBRIATI KADIR**	**ST. FATIMAH**	**ABD. AZIS**	**ABD AZIS**	**MARTINUS**
RM	106432	146180	121775	147821	148267	104396	146027	059638	147225	148299	150121	115471	150135	111586	111586	12014 8204
TANGGAL OPERASI	**10/1/2022**	**15/1/2022**	**17/1/2022**	**22/1/2022**	**24/1/2022**	**24/1/2022**	**24/1/2022**	**24/1/2022**	**24/01/2022**	**28/1/2022**	**29/1/2022**	**29/1/2022**	**29/1/2022**	**21/2/2022**	**14/3/2022**	**21/3/2022**
MATA	**KIRI**	**KANAN**	**KANAN**	**KANAN**	**KIRI**	**KANAN**	**KIRI**	**KIRI**	**KIRI**	**KIRI**	**KIRI**	**KIRI**	**KIRI**	**KANAN**	**KIRI**	**KANAN**
UMUR	70	62	53	89	67	78	58	69	64	68	59	69	58	57	57	59
JK	PEREMPUAN	LAKI-LAKI	LAKI-LAKI	PEREMPUAN	LAKI-LAKI	PEREMPUAN	PEREMPUAN	PEREMPUAN	LAKI-LAKI	PEREMPUAN	LAKI-LAKI	PEREMPUAN	PEREMPUAN	LAKI-LAKI	LAKI-LAKI	LAKI-LAKI
PRE OP																
Visual Acuity (Decimal)	0,25	0,2	0,1	0,25	0,2	0,3	0,03	0,28	0,03	0,25	0,2	0,28	0,1	0,03	0,05	0,28
Visual Acuity (LogMar)	0,60	0,70	1,00	0,60	0,70	0,52	1,52	0,55	1,52	0,60	0,70	0,55	1,00	1,52	1,30	0,55
IOP (mmHg)	14	16	12	12	21	17	17	17	27	18	18	19	17	15	14	14
CENTRAL MACULAR THICKNESS(µm)	227	272	302	228	242	226	248	201	314	221	260	262	241	246	250	228
VOL (mm2)	9,9	10,9	10,3	9,1	9,4	9,2	10,5	8,4	9,8	9,4	11	8,8	9,8	8,8	10,1	8,3
THICK. AVG µm)	276	302	285	254	262	256	291	234	271	260	277	245	273	245	282	231
OP																
Phacoemusification time (sec)	51,8	45,8	60,1	52,5	29	106,1	30,9	50,6	51,4	34,3	30	59,3	30,2	38,9	28	27,7
Effective phaco time (sec)	7,1	8,8	2	11	3	20	2,9	4	7,5	4,3	2,6	11,6	2,5	6,2	4,4	2,8
Operation time (minute)	8	15	15	15	10	15	10	15	20	10	15	10	20	15	15	10
AVG (%)	13,7	19,2	3,3	21,0	10,3	18,9	9,4	7,9	14,6	12,5	8,7	19,6	8,3	15,9	15,7	10,1
POST OP H+1																
VISUS (Decimal)	0,1	0,2	0,5	0,28	0,2	0,01	0,2	0,01	0,5	0,6	0,3	0,05	0,6	0,05	0,5	0,05
VISUS (LogMar)	1,00	0,70	0,30	0,55	0,70	2,00	0,70	2,00	0,30	0,22	0,52	1,30	0,22	1,30	0,30	1,30
IOP (mmHg)	15	15	11	13	22	15	19	22	25	14	24	20	16	15	21	25
CELL	1	0,5	0,5	0,5	0,5	1	0,5	2	0,5	3	0,5	0,5	0	0,5	0	0,5
FLARE	1	1	1	1	1	1	1	2	1	3	0	1	0	1	0	0
CONJUNGTIVA HIPEREMIS	1	0	1	0	1	1	0	1	0	1	0	1	0	1	1	0

PAIN (VAS)	1	1	0	0	1	0	1	1	0	1	1	0	0	0	0	0
POST OP H+7																
VISUS (Decimal)	0,8	0,4	0,6	0,6	0,28	0,3	0,8	0,28	0,8	0,6	0,6	0,5	1	0,5	1	0,3
VISUS (LogMar)	0,10	0,40	0,22	0,22	0,55	0,52	0,10	0,55	0,10	0,22	0,22	0,30	0,00	0,30	0,00	0,52
IOP (mmHg)	13	15	10	13	20	15	19	12	32	17	23	16	14	12	12	13
CENTRAL MACULAR THICKNESS(µm)	225	281	305	213	249	227	247	204	285	226	266	250	237	254	243	228
VOL (mm2)	10	11,1	8,4	8,9	9,6	9,1	10,5	9,8	10,6	9,6	10	9,5	9,7	9,7	10,1	9,2
THICK. AVG µm)	281	310	233	248	267	254	292	272	295	267	279	263	270	271	281	254
CELL	0,5	0	0	0	0	0,5	0	0,5	0	0,5	0	0	0	0	0	0
FLARE	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0
CONJ.HIPEREMIS	0	0	0	0	0	1	0	1	0	1	0	0	1	1	0	0
PAIN	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0
POST OP 30																
VISUS (Decimal)	0,8	1	1	0,8	0,6	1	1	0,8	1	0,8	0,8	1	1	1	1	0,8
VISUS (LogMar)	0,10	0,00	0,00	0,10	0,22	0,00	0,00	0,10	0,00	0,10	0,10	0,00	0,00	0,00	0,00	0,10
NCT	12	11	13	13	13	13	17	12	15	13	15	11	13	11	12	12
CENTRAL MACULAR THICKNESS(µm)	227	251	320	218	262	232	261	209	287	234	285	253	259	250	247	248
VOL (mm2)	9,9	9,2	10,7	9	9,8	9,6	10,6	10	10,4	10,1	10,6	9,6	10,2	10,1	10,3	9,6
THICK. AVG µm)	275	255	296	251	272	267	295	277	288	280	295	267	284	282	286	266
CELL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FLARE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONJ.HIPEREMIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PAIN	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Kelompok Na.Diklofenak post op

No	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
NAMA	**HASLI SABAN G**	**ABD JALI L**	**ST HALIA**	**BAK RI**	**IRENE**	**SAY UTI**	**KAHAR HASAN**	**SEMOG A JAYA**	**THUNG TANG LOE**	**BANG NGA**	**ARA S**	**CUL A**	**RAM LI**	**ARA S**	**NURSIAH HASYIM**	**DAHRI AH**
RM	148628	1505 89	150596	1505 05	150932	1278 07	151246	151263	150189	129166	1514 16	1515 43	1515 50	1514 16	30370	151641
TANGGAL OPERASI	**4/2/2022**	**5/2/2 022**	**5/2/202 2**	**12/2/ 2022**	**12/2/20 22**	**12/2/ 2022**	**18/02/20 22**	**21/02/20 22**	**21/02/202 2**	**25/02/2 022**	**25/02 /2022**	**04/03 /2022**	**04/03 /2022**	**05/03 /2022**	**05/03/202 2**	**21/03/2 022**
MATA	**KANAN**	**KAN AN**	**KANA N**	**KIRI**	**KANA N**	**KIRI**	**KIRI**	**KANAN**	**KANAN**	**KIRI**	**KIRI**	**KIRI**	**KIRI**	**KAN AN**	**KANAN**	**KIRI**
UMUR	62	51	64	59	61	76	59	68	65	76	61	71	70	61	69	67
JK	LAKI-LAKI	LAKI-LAKI	PERE MPUA N	LAKI - LAKI	PERE MPUA N	LAKI - LAKI	LAKI-LAKI	LAKI-LAKI	LAKI-LAKI	PERE MPUA N	LAKI-LAKI	LAKI-LAKI	LAKI-LAKI	LAKI-LAKI	PEREMP UAN	PERE MPUA N
PRE OP																
Visual Acuity (Decimal)	0,3	0,3	0,05	0,28	0,2	0,03	0,25	0,05	0,2	0,03	0,05	0,05	0,3	0,1	0,05	0,4
Visual Acuity (LogMar)	0,52	0,52	1,30	0,55	0,70	1,52	0,60	1,30	0,70	1,52	1,30	1,30	0,52	1,00	1,30	0,40
IOP (mmHg)	19	18	22	16	19	14	13	13	11	14	13	17	18	16	18	17
CENTRAL MACULAR THICKNESS(µm)	247	257	213	226	228	232	259	223	272	260	285	243	243	284	254	230
VOL (mm2)	9,6	9,8	10	20,2	9,2	8,6	10,3	8,4	9,3	9,4	9,7	9,2	9,2	8,5	9,3	9,6
THICK. AVG µm)	267	274	279	279	256	240	286	234	260	261	268	256	256	237	258	268
OP																
Phacoemusification time (sec)	24,4	23,2	30	**54,3**	33,2	45,5	49,7	30,9	40,9	59,9	29,6	60	34,7	39,5	38,9	37,9
Effective phaco time (sec)	5,6	6,1	2,4	4,2	4,8	9,5	3,8	3	2	12,5	8	14	6,6	8	5,1	5,7
Operation time (minute)	10	15	15	15	10	15	10	10	10	10	10	10	10	20	10	10
POST OP H+1																
VISUS (Decimal)	0,25	0,25	0,01	0,3	0,28	0,2	0,25	0,28	0,1	0,2	0,6	0,05	0,3	0,01	0,2	0,6
VISUS (LogMar)	0,60	0,60	2,00	0,52	0,55	0,70	0,60	0,55	1,00	0,70	0,22	1,30	0,52	2,00	0,70	0,22
IOP (mmHg)	19	17	22	22	20	18	25	17	13	17	16	17	14	16	22	11
CELL	0,5	1	1	1	3	1	0,5	0,5	0,5	1	0,5	1	0,5	1	3	0,5
FLARE	1	1	1	1	2	1	1	0	1	0	0	1	0	1	2	0
CONJUNGTIVA HIPEREMIS	0	0	1	2	2	1	1	0	0	1	0	0	0	2	2	0

PAIN (VAS)	0	0	1	0	1	0	0	0	0	1	0	1	0	1	1	0
POST OP H+7																
VISUS (Decimal)	0,6	0,25	0,01	0,4	0,5	0,3	0,5	0,5	0,6	0,5	0,8	0,5	0,4	0,5	0,5	0,8
VISUS (LogMar)	0,22	0,60	2,00	0,40	0,30	0,52	0,30	0,30	0,22	0,30	0,10	0,30	0,40	0,30	0,30	0,10
IOP (mmHg)	15	17	24	18	19	11	11	13	10	19	15	9	11	13	15	12
CENTRAL MACULAR THICKNESS(µm)	247	256	212	226	226	227	261	220	274	262	275	258	276	277	271	221
VOL (mm2)	9,5	9,8	10	10,1	9,8	9,2	10,4	8,9	10,2	10,3	10,3	9,8	8,9	10,5	9,4	9,8
THICK. AVG µm)	263	273	279	281	273	256	288	247	285	287	296	273	246	292	261	272
CELL	0	0,5	0,5	0	0,5	0	0	0	0	0	0	0,5	0	0,5	0,5	0
FLARE	0	0	1	0	1	0	0	0	0	0	0	0	0	0	1	0
CONJUNGTIVA HIPEREMIS	0	0	1	0	1	0	0	0	0	0	0	0	0	0	1	0
PAIN	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
POST OP 30																
VISUS (Decimal)	1	1	0,8	0,5	0,8	0,5	1	1	1	0,5	1	0,5	1	1	0,8	1
VISUS (LogMar)	0,00	0,00	0,10	0,30	0,10	0,30	0,00	0,00	0,00	0,30	0,00	0,30	0,00	0,00	0,10	0,00
IOP (mmHg)	13	14	16	16	16	11	11	9	9	17	14	12	10	14	15	12
CENTRAL MACULAR THICKNESS(µm)	250	267	235	239	227	232	261	231	282	273	279	269	248	285	275	229
VOL (mm2)	9,7	10,2	11,2	10,4	9,9	9,4	10,7	9,3	10,4	10,4	10,5	10,2	9,9	10,6	10,1	9,8
THICK. AVG µm)	270	283	311	289	274	262	296	259	290	288	290	283	275	295	282	271
CELL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CELL AND FLARE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONJUNGTIVA HIPEREMIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PAIN	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Kelompok Na.Diklofenak pre-post op

No	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
NAMA	**JOHANA**	**ANDRIYANI**	**MULIATY**	**JEMMY**	**HAMSYAH**	**RUSLI**	**HAJRAH**	**A.DAENG**	**NURSIAH M**	**RASUL**	**AMRULLAH**	**AMINUDDIN**	**SYAMSUDDIN S**	**KAMRIA**	**HERLINA**	**NILAWATY**
RM	1512100	127533	151844	151921	131936	151005	152077	85147	152130	152166	152450	134536	132830	53971	152556	152522
OP	7/3/2022	7/3/2022	07/03/2022	07/03/2022	7/3/2022	11/3/2022	11/3/2022	14/3/2022	14/3/2022	17/3/2022	18/3/2022	18/3/2022	21/3/2022	21/3/2022	21/3/2022	21/3/2022
MATA	**KANAN**	**KIRI**	**KIRI**	**KANAN**	**KIRI**	**KIRI**	**KANAN**	**KIRI**	**KIRI**	**KANAN**	**KIRI**	**KANAN**	**KANAN**	**KANAN**	**KANAN**	**KIRI**
UMUR	69	56	65	58	57	73	66	53	56	66	65	73	72	75	71	67
JK	PEREMPUAN	PEREMPUAN	PEREMPUAN	LAKI-LAKI	LAKI-LAKI	LAKI-LAKI	PEREMPUAN	LAKI-LAKI	PEREMPUAN	LAKI-LAKI	LAKI-LAKI	LAKI-LAKI	LAKI-LAKI	PEREMPUAN	PEREMPUAN	PEREMPUAN
PRE OP																
Visual Acuity (Decimal)	0,25	0,03	0,05	0,2	0,03	0,02	0,28	0,03	0,05	0,05	0,32	0,1	0,05	0,1	0,28	0,28
Visual Acuity (LogMar)	0,60	1,52	1,30	0,70	1,52	1,70	0,55	1,52	1,30	1,30	0,49	1,00	1,30	1,00	0,55	0,55
IOP (mmHg)	18	14	20	15	16	14	14	20	17	19	14	15	17	12	14	12
CENTRAL MACULAR THICKNESS(µm)	234	258	262	232	253	222	244	218	259	274	273	247	256	241	242	241
VOL (mm2)	10,5	9,8	9,1	9,9	10,1	8,9	9,5	9,9	8,6	9,9	10,6	8,9	8,7	9	9,7	8,9
THICK. AVG µm)	292	273	253	276	280	248	263	275	240	275	295	247	241	250	270	249
OP																
Phacoemusification time (sec)	46	52,1	45,3	28,5	56,6	36,4	37,8	43,4	26,3	23,1	27,3	35	43,6	18	24,5	57,19
Effective phaco time (sec)	3	6,4	6,3	4	7,4	4,8	3,4	7,2	3,5	18	1,9	16,4	8,9	12,7	3,5	8,3
Operation time (minute)	10	10	10	10	10	15	15	10	13	18	10	15	15	10	10	10
POST OP H+1																
Visual Acuity (Decimal)	0,05	0,5	0,4	0,4	0,05	0,05	0,6	0,08	0,1	0,05	0,3	0,08	0,3	0,1	0,8	0,2
Visual Acuity (LogMar)	1,30	0,30	0,40	0,40	1,30	1,30	0,22	1,10	1,00	1,30	0,52	1,10	0,52	1,00	0,10	0,70
IOP (mmHg)	23	14	20	23	24	21	16	28	17	25	22	23	24	15	15	17
CELL	0,5	0	0,5	0	0,5	0,5	0	0,5	1	1	0,5	0,5	0,5	0,5	0	0,5
FLARE	1	0	0	0	1	1	0	1	1	2	0	1	0	1	0	0
CONJUNGTIVA HIPEREMIS	1	1	1	0	0	1	0	1	1	1	0	1	0	0	0	0
PAIN (VAS)	0	1	2	0	0	0	0	0	1	1	0	0	0	0	0	0

POST OP H+7																
Visual Acuity (Decimal)	1	0,5	0,5	0,8	0,6	0,3	0,6	0,6	0,5	0,28	0,3	0,2	0,8	0,28	0,8	0,8
Visual Acuity (LogMar)	0,00	0,30	0,30	0,10	0,22	0,52	0,22	0,22	0,30	0,55	0,52	0,70	0,10	0,55	0,10	0,10
IOP (mmHg)	16	13	23	13	21	18	13	23	14	12	14	14	16	14	15	15
CENTRAL MACULAR THICKNESS(µm)	230	261	258	221	247	212	255	207	255	268	268	244	253	227	239	236
VOL (mm2)	10,8	10,6	10,6	9,8	10,1	9,9	9,8	9,5	10,1	11	10,5	10	9,8	8,8	9,5	7,8
THICK. AVG µm)	299	294	293	272	280	274	263	264	282	306	292	279	273	245	264	218
CELL	0,5	0	0	0	0	0	0	0	0,5	0,5	0	0	0	0	0	0
FLARE	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0
CONJUNGTIVA HIPEREMIS	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0
PAIN	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
POST OP 30																
Visual Acuity (Decimal)	1	1	0,5	1	1	0,8	1	1	1	0,8	1	1	1	1	1	1
Visual Acuity (LogMar)	0,00	0,00	0,30	0,00	0,00	0,10	0,00	0,00	0,00	0,10	0,00	0,00	0,00	0,00	0,00	0,00
IOP (mmHg)	15	13	21	13	14	12	13	19	14	12	13	16	16	14	16	12
CENTRAL MACULAR THICKNESS(µm)	244	262	261	222	248	212	268	222	257	264	269	250	261	230	252	238
VOL (mm2)	11,1	10,5	10,4	9,5	10,2	9,9	10	9,9	10,2	7,1	10,7	10,4	10	9,6	10	9,6
THICK. AVG µm)	309	291	289	263	283	274	276	276	285	197	296	289	278	267	279	266
CELL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FLARE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONJ.HIPEREMIS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PAIN	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Umur * Group Crosstabulation

			Group				
			P-Pred (Post)	P-Pred (Pre-Post)	Na.Dic (Post)	Na.Dic (Pre-Post)	Total
Umur	50-60	Count	2	7	3	5	17
		% within Group	12.5%	43.8%	18.8%	31.3%	26.6%
	>60	Count	14	9	13	11	47
		% within Group	87.5%	56.3%	81.3%	68.8%	73.4%
Total		Count	16	16	16	16	64

JK * Group Crosstabulation

			Group				
			P-Pred (Post)	P-Pred (Pre-Post)	Na.Dic (Post)	Na.Dic (Pre-Post)	Total
JK	Laki-laki	Count	9	8	11	8	36
		% within Group	56.3%	50.0%	68.8%	50.0%	56.3%
	Perempuan	Count	7	8	5	8	28
		% within Group	43.8%	50.0%	31.3%	50.0%	43.8%
Total		Count	16	16	16	16	64
		% within Group	100.0%	100.0%	100.0%	100.0%	100.0%

Lateralisasi * Group Crosstabulation

			Group				
			P-Pred (Post)	P-Pred (Pre-Post)	Na.Dic (Post)	Na.Dic (Pre-Post)	Total
Lateralisasi	Kiri	Count	11	10	8	8	37
		% within Group	68.8%	62.5%	50.0%	50.0%	57.8%
	Kanan	Count	5	6	8	8	27
		% within Group	31.3%	37.5%	50.0%	50.0%	42.2%
Total		Count	16	16	16	16	64
		% within Group	100.0%	100.0%	100.0%	100.0%	100.0%

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
CMTPre	Equal variances assumed	.964	.334	-.515	30	.611	-4.625	8.986	-22.976	13.726
	Equal variances not assumed			-.515	26.957	.611	-4.625	8.986	-23.063	13.813
CMT7	Equal variances assumed	.003	.960	-.257	30	.799	-2.375	9.232	-21.230	16.480
	Equal variances not assumed			-.257	29.740	.799	-2.375	9.232	-21.237	16.487
CMT30	Equal variances assumed	.181	.674	-.083	30	.935	-.813	9.818	-20.863	19.238
	Equal variances not assumed			-.083	30.000	.935	-.813	9.818	-20.863	19.238

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
CMTPre	Equal variances assumed	1.463	.236	.000	30	1.000	.000	6.756	-13.799	13.799
	Equal variances not assumed			.000	27.905	1.000	.000	6.756	-13.842	13.842
CMT7	Equal variances assumed	2.138	.154	.893	30	.379	6.750	7.558	-8.686	22.186
	Equal variances not assumed			.893	28.760	.379	6.750	7.558	-8.714	22.214
CMT30	Equal variances assumed	1.724	.199	1.106	30	.278	7.625	6.897	-6.460	21.710

Equal variances not assumed			1.106	29.285	.278	7.625	6.897	-6.475	21.725

Correlations

		CMTPre	CMT30	Phacotime
CMTPre	Pearson Correlation	1	.888**	.467
	Sig. (2-tailed)		.000	.068
	Sum of Squares and Cross-products	6433.750	7665.750	3185.550
	Covariance	428.917	511.050	212.370
	N	16	16	16
CMT30	Pearson Correlation	.888**	1	.240
	Sig. (2-tailed)	.000		.372
	Sum of Squares and Cross-products	7665.750	11571.750	2190.150
	Covariance	511.050	771.450	146.010
	N	16	16	16
Phacotime	Pearson Correlation	.467	.240	1
	Sig. (2-tailed)	.068	.372	
	Sum of Squares and Cross-products	3185.550	2190.150	7223.510
	Covariance	212.370	146.010	481.567
	N	16	16	16

**. Correlation is significant at the 0.01 level (2-tailed).

Correlations

		CMTPre	CMT30	Phacotime
CMTPre	Pearson Correlation	1	.857**	.022
	Sig. (2-tailed)		.000	.937
	Sum of Squares and Cross-products	12944.000	10485.000	189.700
	Covariance	862.933	699.000	12.647
	N	16	16	16
CMT30	Pearson Correlation	.857**	1	-.139
	Sig. (2-tailed)	.000		.608

	Sum of Squares and Cross-products	10485.000	11561.438	-1154.538
	Covariance	699.000	770.763	-76.969
	N	16	16	16
Phacotime	Pearson Correlation	.022	-.139	1
	Sig. (2-tailed)	.937	.608	
	Sum of Squares and Cross-products	189.700	-1154.538	5977.277
	Covariance	12.647	-76.969	398.485
	N	16	16	16

**. Correlation is significant at the 0.01 level (2-tailed).

Correlations

		CMTPre	CMT30	Phacotime
CMTPre	Pearson Correlation	1	.906**	.024
	Sig. (2-tailed)		.000	.928
	Sum of Squares and Cross-products	6979.000	6145.500	91.750
	Covariance	465.267	409.700	6.117
	N	16	16	16
CMT30	Pearson Correlation	.906**	1	.180
	Sig. (2-tailed)	.000		.505
	Sum of Squares and Cross-products	6145.500	6599.750	656.625
	Covariance	409.700	439.983	43.775
	N	16	16	16
Phacotime	Pearson Correlation	.024	.180	1
	Sig. (2-tailed)	.928	.505	
	Sum of Squares and Cross-products	91.750	656.625	2018.997
	Covariance	6.117	43.775	134.600
	N	16	16	16

**. Correlation is significant at the 0.01 level (2-tailed).

Correlations

		CMTPre	CMT30	Phacotime
CMTPre	Pearson Correlation	1	.906**	.024
	Sig. (2-tailed)		.000	.928
	Sum of Squares and Cross-products	6979.000	6145.500	91.750
	Covariance	465.267	409.700	6.117
	N	16	16	16
CMT30	Pearson Correlation	.906**	1	.180
	Sig. (2-tailed)	.000		.505
	Sum of Squares and Cross-products	6145.500	6599.750	656.625
	Covariance	409.700	439.983	43.775
	N	16	16	16
Phacotime	Pearson Correlation	.024	.180	1
	Sig. (2-tailed)	.928	.505	
	Sum of Squares and Cross-products	91.750	656.625	2018.997
	Covariance	6.117	43.775	134.600
	N	16	16	16

**. Correlation is significant at the 0.01 level (2-tailed).

Tests of Within-Subjects Effects

Measure: MEASURE_1

Source		Type III Sum of Squares	df	Mean Square	F	Sig.
CMT	Sphericity Assumed	1471.531	2	735.766	13.000	.000
	Greenhouse-Geisser	1471.531	1.800	817.740	13.000	.000
	Huynh-Feldt	1471.531	1.849	795.790	13.000	.000
	Lower-bound	1471.531	1.000	1471.531	13.000	.001
Error(CMT)	Sphericity Assumed	7131.135	126	56.596		
	Greenhouse-Geisser	7131.135	113.369	62.902		
	Huynh-Feldt	7131.135	116.496	61.213		
	Lower-bound	7131.135	63.000	113.193		

Tests of Within-Subjects Effects

Measure: MEASURE_1

Source		Type III Sum of Squares	df	Mean Square	F	Sig.

BCVA	Sphericity Assumed	31.693	3	10.564	86.253	.000
	Greenhouse-Geisser	31.693	2.203	14.384	86.253	.000
	Huynh-Feldt	31.693	2.405	13.177	86.253	.000
	Lower-bound	31.693	1.000	31.693	86.253	.000
BCVA * Group	Sphericity Assumed	.757	9	.084	.687	.720
	Greenhouse-Geisser	.757	6.610	.115	.687	.675
	Huynh-Feldt	.757	7.216	.105	.687	.687
	Lower-bound	.757	3.000	.252	.687	.564
Error(BCVA)	Sphericity Assumed	22.047	180	.122		
	Greenhouse-Geisser	22.047	132.202	.167		
	Huynh-Feldt	22.047	144.315	.153		
	Lower-bound	22.047	60.000	.367		

Tests of Within-Subjects Effects

Measure: MEASURE_1

Source		Type III Sum of Squares	df	Mean Square	F	Sig.
IOP	Sphericity Assumed	1183.281	3	394.427	56.415	.000
	Greenhouse-Geisser	1183.281	2.470	478.965	56.415	.000
	Huynh-Feldt	1183.281	2.714	436.057	56.415	.000
	Lower-bound	1183.281	1.000	1183.281	56.415	.000
IOP * Group	Sphericity Assumed	151.250	9	16.806	2.404	.013
	Greenhouse-Geisser	151.250	7.411	20.408	2.404	.021
	Huynh-Feldt	151.250	8.141	18.579	2.404	.017
	Lower-bound	151.250	3.000	50.417	2.404	.076
Error(IOP)	Sphericity Assumed	1258.469	180	6.991		
	Greenhouse-Geisser	1258.469	148.230	8.490		
	Huynh-Feldt	1258.469	162.816	7.729		
	Lower-bound	1258.469	60.000	20.974		

Tests of Within-Subjects Effects

Measure: MEASURE_1

Source		Type III Sum of Squares	df	Mean Square	F	Sig.
Cell	Sphericity Assumed	18.862	2	9.431	121.527	.000
	Greenhouse-Geisser	18.862	1.356	13.913	121.527	.000
	Huynh-Feldt	18.862	1.445	13.049	121.527	.000
	Lower-bound	18.862	1.000	18.862	121.527	.000
Cell * Group	Sphericity Assumed	1.659	6	.276	3.563	.003
	Greenhouse-Geisser	1.659	4.067	.408	3.563	.010
	Huynh-Feldt	1.659	4.336	.383	3.563	.008
	Lower-bound	1.659	3.000	.553	3.563	.019
Error(Cell)	Sphericity Assumed	9.313	120	.078		
	Greenhouse-Geisser	9.313	81.344	.114		
	Huynh-Feldt	9.313	86.727	.107		
	Lower-bound	9.313	60.000	.155		

Tests of Within-Subjects Effects

Measure: MEASURE_1

Source		Type III Sum of Squares	df	Mean Square	F	Sig.
Flare	Sphericity Assumed	19.500	2	9.750	67.500	.000
	Greenhouse-Geisser	19.500	1.490	13.085	67.500	.000
	Huynh-Feldt	19.500	1.596	12.218	67.500	.000
	Lower-bound	19.500	1.000	19.500	67.500	.000
Flare * Group	Sphericity Assumed	1.167	6	.194	1.346	.242
	Greenhouse-Geisser	1.167	4.471	.261	1.346	.256
	Huynh-Feldt	1.167	4.788	.244	1.346	.253
	Lower-bound	1.167	3.000	.389	1.346	.268
Error(Flare)	Sphericity Assumed	17.333	120	.144		
	Greenhouse-Geisser	17.333	89.418	.194		
	Huynh-Feldt	17.333	95.757	.181		
	Lower-bound	17.333	60.000	.289		

Tests of Within-Subjects Effects

Measure: MEASURE_1

Source		Type III Sum of Squares	df	Mean Square	F	Sig.
Nyeri	Sphericity Assumed	6.844	2	3.422	36.468	.000
	Greenhouse-Geisser	6.844	1.266	5.405	36.468	.000
	Huynh-Feldt	6.844	1.280	5.345	36.468	.000
	Lower-bound	6.844	1.000	6.844	36.468	.000
Error(Nyeri)	Sphericity Assumed	11.823	126	.094		
	Greenhouse-Geisser	11.823	79.777	.148		
	Huynh-Feldt	11.823	80.665	.147		
	Lower-bound	11.823	63.000	.188		

Tests of Within-Subjects Effects

Measure: MEASURE_1

Source		Type III Sum of Squares	df	Mean Square	F	Sig.
Konjungtiva	Sphericity Assumed	15.823	2	7.911	49.405	.000
	Greenhouse-Geisser	15.823	1.494	10.590	49.405	.000
	Huynh-Feldt	15.823	1.522	10.394	49.405	.000
	Lower-bound	15.823	1.000	15.823	49.405	.000
Error(Konjungtiva)	Sphericity Assumed	20.177	126	.160		
	Greenhouse-Geisser	20.177	94.133	.214		
	Huynh-Feldt	20.177	95.901	.210		
	Lower-bound	20.177	63.000	.320		

Crosstab

			Group				
			P-Pred (Post)	P-Pred (Pre-Post)	Na.Dic (Post)	Na.Dic (Pre-Post)	Total
Cell1	.0	Count	1	1	0	4	6
		% within Group	6.3%	6.3%	0.0%	25.0%	9.4%

	.5	Count	7	7	7	10	31
		% within Group	43.8%	43.8%	43.8%	62.5%	48.4%
	1.0	Count	8	8	7	2	25
		% within Group	50.0%	50.0%	43.8%	12.5%	39.1%
	3.0	Count	0	0	2	0	2
		% within Group	0.0%	0.0%	12.5%	0.0%	3.1%
Total		Count	16	16	16	16	64
		% within Group	100.0%	100.0%	100.0%	100.0%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	16.831[a]	9	.051
Likelihood Ratio	17.521	9	.041
Linear-by-Linear Association	.838	1	.360
N of Valid Cases	64		

a. 8 cells (50.0%) have expected count less than 5. The minimum expected count is .50.

Crosstab

			Group				
			P-Pred (Post)	P-Pred (Pre-Post)	Na.Dic (Post)	Na.Dic (Pre-Post)	Total
Cell7	.0	Count	10	12	10	13	45
		% within Group	62.5%	75.0%	62.5%	81.3%	70.3%
	.5	Count	6	4	6	3	19
		% within Group	37.5%	25.0%	37.5%	18.8%	29.7%
Total		Count	16	16	16	16	64
		% within Group	100.0%	100.0%	100.0%	100.0%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	2.021[a]	3	.568
Likelihood Ratio	2.071	3	.558
Linear-by-Linear Association	.722	1	.395
N of Valid Cases	64		

a. 4 cells (50.0%) have expected count less than 5. The minimum expected count is 4.75.

Crosstab

			Group				
			P-Pred (Post)	P-Pred (Pre-Post)	Na.Dic (Post)	Na.Dic (Pre-Post)	Total
Cell30	.0	Count	16	16	16	16	64
		% within Group	100.0%	100.0%	100.0%	100.0%	100.0%

Total		Count	16	16	16	16	64
		% within Group	100.0%	100.0%	100.0%	100.0%	100.0%

Chi-Square Tests

	Value
Pearson Chi-Square	.[a]
N of Valid Cases	64

a. No statistics are computed because Cell30 is a constant.

Crosstab

			Group				
			P-Pred (Post)	P-Pred (Pre-Post)	Na.Dic (Post)	Na.Dic (Pre-Post)	Total
Flare1	.0	Count	6	4	5	8	23
		% within Group	37.5%	25.0%	31.3%	50.0%	35.9%
	1.0	Count	9	10	9	7	35
		% within Group	56.3%	62.5%	56.3%	43.8%	54.7%
	2.0	Count	1	1	2	1	5
		% within Group	6.3%	6.3%	12.5%	6.3%	7.8%
	3.0	Count	0	1	0	0	1
		% within Group	0.0%	6.3%	0.0%	0.0%	1.6%
Total		Count	16	16	16	16	64
		% within Group	100.0%	100.0%	100.0%	100.0%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	5.665[a]	9	.773
Likelihood Ratio	5.368	9	.801
Linear-by-Linear Association	.450	1	.502
N of Valid Cases	64		

a. 8 cells (50.0%) have expected count less than 5. The minimum expected count is .25.

Crosstab

			Group				
			P-Pred (Post)	P-Pred (Pre-Post)	Na.Dic (Post)	Na.Dic (Pre-Post)	Total
Flare7	.0	Count	11	14	13	14	52
		% within Group	68.8%	87.5%	81.3%	87.5%	81.3%
	1.0	Count	5	2	3	2	12
		% within Group	31.3%	12.5%	18.8%	12.5%	18.8%
Total		Count	16	16	16	16	64

	% within Group	100.0%	100.0%	100.0%	100.0%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	2.462[a]	3	.482
Likelihood Ratio	2.339	3	.505
Linear-by-Linear Association	1.292	1	.256
N of Valid Cases	64		

a. 4 cells (50.0%) have expected count less than 5. The minimum expected count is 3.00.

Crosstab

			Group				
			P-Pred (Post)	P-Pred (Pre-Post)	Na.Dic (Post)	Na.Dic (Pre-Post)	Total
Flare30	.0	Count	16	16	16	16	64
		% within Group	100.0%	100.0%	100.0%	100.0%	100.0%
Total		Count	16	16	16	16	64
		% within Group	100.0%	100.0%	100.0%	100.0%	100.0%

Chi-Square Tests

	Value
Pearson Chi-Square	.[a]
N of Valid Cases	64

a. No statistics are computed because Flare30 is a constant.

Crosstab

			Group				
			P-Pred (Post)	P-Pred (Pre-Post)	Na.Dic (Post)	Na.Dic (Pre-Post)	Total
Nyeri1	0	Count	6	9	10	12	37
		% within Group	37.5%	56.3%	62.5%	75.0%	57.8%
	1	Count	10	7	6	4	27
		% within Group	62.5%	43.8%	37.5%	25.0%	42.2%
Total		Count	16	16	16	16	64
		% within Group	100.0%	100.0%	100.0%	100.0%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	4.805[a]	3	.187

Likelihood Ratio	4.889	3	.180
Linear-by-Linear Association	4.553	1	.033
N of Valid Cases	64		

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 6.75.

Crosstab

			Group				
			P-Pred (Post)	P-Pred (Pre-Post)	Na.Dic (Post)	Na.Dic (Pre-Post)	Total
Nyeri7	0	Count	16	14	15	16	61
		% within Group	100.0%	87.5%	93.8%	100.0%	95.3%
	1	Count	0	2	1	0	3
		% within Group	0.0%	12.5%	6.3%	0.0%	4.7%
Total		Count	16	16	16	16	64
		% within Group	100.0%	100.0%	100.0%	100.0%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	3.847[a]	3	.278
Likelihood Ratio	4.681	3	.197
Linear-by-Linear Association	.069	1	.793
N of Valid Cases	64		

a. 4 cells (50.0%) have expected count less than 5. The minimum expected count is .75.

Crosstab

			Group				
			P-Pred (Post)	P-Pred (Pre-Post)	Na.Dic (Post)	Na.Dic (Pre-Post)	Total
Nyeri30	0	Count	16	16	16	16	64
		% within Group	100.0%	100.0%	100.0%	100.0%	100.0%
Total		Count	16	16	16	16	64
		% within Group	100.0%	100.0%	100.0%	100.0%	100.0%

Chi-Square Tests

	Value
Pearson Chi-Square	.[a]
N of Valid Cases	64

a. No statistics are computed because Nyeri30 is a constant.

Crosstab

			Group				
			P-Pred (Post)	P-Pred (Pre-Post)	Na.Dic (Post)	Na.Dic (Pre-Post)	Total
Konjungtiva1	0	Count	3	7	8	8	26
		% within Group	18.8%	43.8%	50.0%	50.0%	40.6%
	1	Count	11	9	4	8	32
		% within Group	68.8%	56.3%	25.0%	50.0%	50.0%
	2	Count	2	0	4	0	6
		% within Group	12.5%	0.0%	25.0%	0.0%	9.4%
Total		Count	16	16	16	16	64
		% within Group	100.0%	100.0%	100.0%	100.0%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	13.199[a]	6	.040
Likelihood Ratio	15.621	6	.016
Linear-by-Linear Association	2.477	1	.116
N of Valid Cases	64		

a. 4 cells (33.3%) have expected count less than 5. The minimum expected count is 1.50.

Crosstab

			Group				
			P-Pred (Post)	P-Pred (Pre-Post)	Na.Dic (Post)	Na.Dic (Pre-Post)	Total
Konjungtiva7	0	Count	15	11	13	14	53
		% within Group	93.8%	68.8%	81.3%	87.5%	82.8%
	1	Count	1	5	3	2	11
		% within Group	6.3%	31.3%	18.8%	12.5%	17.2%
Total		Count	16	16	16	16	64
		% within Group	100.0%	100.0%	100.0%	100.0%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	3.842[a]	3	.279
Likelihood Ratio	3.877	3	.275
Linear-by-Linear Association	.022	1	.883
N of Valid Cases	64		

a. 4 cells (50.0%) have expected count less than 5. The minimum expected count is 2.75.

Crosstab

			Group				
			P-Pred (Post)	P-Pred (Pre-Post)	Na.Dic (Post)	Na.Dic (Pre-Post)	Total
Konjungtiva30	0	Count	15	16	16	16	63
		% within Group	93.8%	100.0%	100.0%	100.0%	98.4%
	1	Count	1	0	0	0	1
		% within Group	6.3%	0.0%	0.0%	0.0%	1.6%
Total		Count	16	16	16	16	64
		% within Group	100.0%	100.0%	100.0%	100.0%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	3.048[a]	3	.384
Likelihood Ratio	2.821	3	.420
Linear-by-Linear Association	1.800	1	.180
N of Valid Cases	64		

a. 4 cells (50.0%) have expected count less than 5. The minimum expected count is .25.

Multiple Comparisons

LSD

Dependent Variable	(I) Group	(J) Group	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
						Lower Bound	Upper Bound
Cell1	P-Pred (Post)	P-Pred (Pre-Post)	.0000	.1716	1.000	-.343	.343
		Na.Dic (Post)	-.3125	.1716	.074	-.656	.031
		Na.Dic (Pre-Post)	.2813	.1716	.107	-.062	.625
		P-Pred (Post)	.0000	.1716	1.000	-.343	.343

	P-Pred (Pre-Post)	Na.Dic (Post)	-.3125	.1716	.074	-.656	.031
		Na.Dic (Pre-Post)	.2813	.1716	.107	-.062	.625
	Na.Dic (Post)	P-Pred (Post)	.3125	.1716	.074	-.031	.656
		P-Pred (Pre-Post)	.3125	.1716	.074	-.031	.656
		Na.Dic (Pre-Post)	.5938*	.1716	.001	.250	.937
	Na.Dic (Pre-Post)	P-Pred (Post)	-.2813	.1716	.107	-.625	.062
		P-Pred (Pre-Post)	-.2813	.1716	.107	-.625	.062
		Na.Dic (Post)	-.5938*	.1716	.001	-.937	-.250
Cell7	P-Pred (Post)	P-Pred (Pre-Post)	.0625	.0821	.449	-.102	.227
		Na.Dic (Post)	.0000	.0821	1.000	-.164	.164
		Na.Dic (Pre-Post)	.0938	.0821	.258	-.070	.258
	P-Pred (Pre-Post)	P-Pred (Post)	-.0625	.0821	.449	-.227	.102
		Na.Dic (Post)	-.0625	.0821	.449	-.227	.102
		Na.Dic (Pre-Post)	.0313	.0821	.705	-.133	.195
	Na.Dic (Post)	P-Pred (Post)	.0000	.0821	1.000	-.164	.164
		P-Pred (Pre-Post)	.0625	.0821	.449	-.102	.227
		Na.Dic (Pre-Post)	.0938	.0821	.258	-.070	.258
	Na.Dic (Pre-Post)	P-Pred (Post)	-.0938	.0821	.258	-.258	.070
		P-Pred (Pre-Post)	-.0313	.0821	.705	-.195	.133
		Na.Dic (Post)	-.0938	.0821	.258	-.258	.070
Flare1	P-Pred (Post)	P-Pred (Pre-Post)	-.2500	.2361	.294	-.722	.222
		Na.Dic (Post)	-.1250	.2361	.598	-.597	.347
		Na.Dic (Pre-Post)	.1250	.2361	.598	-.347	.597
	P-Pred (Pre-Post)	P-Pred (Post)	.2500	.2361	.294	-.222	.722
		Na.Dic (Post)	.1250	.2361	.598	-.347	.597
		Na.Dic (Pre-Post)	.3750	.2361	.117	-.097	.847
	Na.Dic (Post)	P-Pred (Post)	.1250	.2361	.598	-.347	.597
		P-Pred (Pre-Post)	-.1250	.2361	.598	-.597	.347
		Na.Dic (Pre-Post)	.2500	.2361	.294	-.222	.722
	Na.Dic (Pre-Post)	P-Pred (Post)	-.1250	.2361	.598	-.597	.347
		P-Pred (Pre-Post)	-.3750	.2361	.117	-.847	.097
		Na.Dic (Post)	-.2500	.2361	.294	-.722	.222
Flare7	P-Pred (Post)	P-Pred (Pre-Post)	.1875	.1398	.185	-.092	.467

		Na.Dic (Post)	.1250	.1398	.375	-.155	.405
		Na.Dic (Pre-Post)	.1875	.1398	.185	-.092	.467
	P-Pred (Pre-Post)	P-Pred (Post)	-.1875	.1398	.185	-.467	.092
		Na.Dic (Post)	-.0625	.1398	.656	-.342	.217
		Na.Dic (Pre-Post)	.0000	.1398	1.000	-.280	.280
	Na.Dic (Post)	P-Pred (Post)	-.1250	.1398	.375	-.405	.155
		P-Pred (Pre-Post)	.0625	.1398	.656	-.217	.342
		Na.Dic (Pre-Post)	.0625	.1398	.656	-.217	.342
	Na.Dic (Pre-Post)	P-Pred (Post)	-.1875	.1398	.185	-.467	.092
		P-Pred (Pre-Post)	.0000	.1398	1.000	-.280	.280
		Na.Dic (Post)	-.0625	.1398	.656	-.342	.217
Nyeri1	P-Pred (Post)	P-Pred (Pre-Post)	.188	.173	.284	-.16	.53
		Na.Dic (Post)	.250	.173	.155	-.10	.60
		Na.Dic (Pre-Post)	.375*	.173	.035	.03	.72
	P-Pred (Pre-Post)	P-Pred (Post)	-.188	.173	.284	-.53	.16
		Na.Dic (Post)	.063	.173	.720	-.28	.41
		Na.Dic (Pre-Post)	.188	.173	.284	-.16	.53
	Na.Dic (Post)	P-Pred (Post)	-.250	.173	.155	-.60	.10
		P-Pred (Pre-Post)	-.063	.173	.720	-.41	.28
		Na.Dic (Pre-Post)	.125	.173	.474	-.22	.47
	Na.Dic (Pre-Post)	P-Pred (Post)	-.375*	.173	.035	-.72	-.03
		P-Pred (Pre-Post)	-.188	.173	.284	-.53	.16
		Na.Dic (Post)	-.125	.173	.474	-.47	.22
Nyeri7	P-Pred (Post)	P-Pred (Pre-Post)	-.125	.075	.100	-.27	.02
		Na.Dic (Post)	-.063	.075	.407	-.21	.09
		Na.Dic (Pre-Post)	.000	.075	1.000	-.15	.15
	P-Pred (Pre-Post)	P-Pred (Post)	.125	.075	.100	-.02	.27
		Na.Dic (Post)	.063	.075	.407	-.09	.21
		Na.Dic (Pre-Post)	.125	.075	.100	-.02	.27
	Na.Dic (Post)	P-Pred (Post)	.063	.075	.407	-.09	.21
		P-Pred (Pre-Post)	-.063	.075	.407	-.21	.09
		Na.Dic (Pre-Post)	.063	.075	.407	-.09	.21
		P-Pred (Post)	.000	.075	1.000	-.15	.15

	Na.Dic (Pre-Post)	P-Pred (Pre-Post)	-.125	.075	.100	-.27	.02
		Na.Dic (Post)	-.063	.075	.407	-.21	.09
Konjungtiva 1	P-Pred (Post)	P-Pred (Pre-Post)	.375	.223	.098	-.07	.82
		Na.Dic (Post)	.188	.223	.404	-.26	.63
		Na.Dic (Pre-Post)	.438	.223	.054	-.01	.88
	P-Pred (Pre-Post)	P-Pred (Post)	-.375	.223	.098	-.82	.07
		Na.Dic (Post)	-.188	.223	.404	-.63	.26
		Na.Dic (Pre-Post)	.063	.223	.780	-.38	.51
	Na.Dic (Post)	P-Pred (Post)	-.188	.223	.404	-.63	.26
		P-Pred (Pre-Post)	.188	.223	.404	-.26	.63
		Na.Dic (Pre-Post)	.250	.223	.267	-.20	.70
	Na.Dic (Pre-Post)	P-Pred (Post)	-.438	.223	.054	-.88	.01
		P-Pred (Pre-Post)	-.063	.223	.780	-.51	.38
		Na.Dic (Post)	-.250	.223	.267	-.70	.20
Konjungtiva 7	P-Pred (Post)	P-Pred (Pre-Post)	-.250	.134	.066	-.52	.02
		Na.Dic (Post)	-.125	.134	.353	-.39	.14
		Na.Dic (Pre-Post)	-.063	.134	.642	-.33	.20
	P-Pred (Pre-Post)	P-Pred (Post)	.250	.134	.066	-.02	.52
		Na.Dic (Post)	.125	.134	.353	-.14	.39
		Na.Dic (Pre-Post)	.188	.134	.166	-.08	.45
	Na.Dic (Post)	P-Pred (Post)	.125	.134	.353	-.14	.39
		P-Pred (Pre-Post)	-.125	.134	.353	-.39	.14
		Na.Dic (Pre-Post)	.063	.134	.642	-.20	.33
	Na.Dic (Pre-Post)	P-Pred (Post)	.063	.134	.642	-.20	.33
		P-Pred (Pre-Post)	-.188	.134	.166	-.45	.08
		Na.Dic (Post)	-.063	.134	.642	-.33	.20
Konjungtiva 30	P-Pred (Post)	P-Pred (Pre-Post)	.063	.044	.162	-.03	.15
		Na.Dic (Post)	.063	.044	.162	-.03	.15
		Na.Dic (Pre-Post)	.063	.044	.162	-.03	.15
	P-Pred (Pre-Post)	P-Pred (Post)	-.063	.044	.162	-.15	.03
		Na.Dic (Post)	.000	.044	1.000	-.09	.09
		Na.Dic (Pre-Post)	.000	.044	1.000	-.09	.09
	Na.Dic (Post)	P-Pred (Post)	-.063	.044	.162	-.15	.03

		P-Pred (Pre-Post)	.000	.044	1.000	-.09	.09
		Na.Dic (Pre-Post)	.000	.044	1.000	-.09	.09
	Na.Dic (Pre-Post)	P-Pred (Post)	-.063	.044	.162	-.15	.03
		P-Pred (Pre-Post)	.000	.044	1.000	-.09	.09
		Na.Dic (Post)	.000	.044	1.000	-.09	.09

*. The mean difference is significant at the 0.05 level.